What is INBX's current stock price?

INBX (Inhibrx Biosciences, Inc.) is currently trading at $101.32 with a market cap of $1.49B.

What sector is Inhibrx Biosciences, Inc. in?

Inhibrx Biosciences, Inc. (INBX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is INBX a good stock to buy?

Analysts have a Buy consensus on INBX with a price target of $325.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

INBX Inhibrx Biosciences, Inc.

Healthcare

$101.32-8.37%ClosedMarket Cap: $1.49B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-75.07

P/S

1143.45

EV/EBITDA

-11.36

DCF Value

$0.74

FCF Yield

-8.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

-35.6%

Operating Margin

-9465.5%

Net Margin

-10014.2%

ROE

-563.9%

ROA

-70.8%

ROIC

-77.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-33.4M	$—
Q4 null	$0.00	$-32.8M	$—
FY null	$1.3M	$-140.1M	$—
Q3 null	$0.00	$-35.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$325.00

Target (Median)

$325.00

Target Range

$325.00 - $325.00

0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

JMP SecuritiesMarket Perform

2025-08-22

Trading Activity

Insider Trades

View All

Matly Davidofficer: President

SellMon Apr 27

VIKING GLOBAL INVESTORS LP10 percent owner

SellThu Oct 09

VIKING GLOBAL INVESTORS LP10 percent owner

SellThu Oct 09

VIKING GLOBAL INVESTORS LP10 percent owner

SellThu Oct 09

Vuori Kristiina MDdirector

SellThu May 29

Latest News

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can ContinueSeeking Alpha · Wed Apr 22

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerPRNewsWire · Mon Apr 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

3.89

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Peers